Obviousness

US patent 12156533 (US'533) relates to nicotine salt formulations for aerosol devices, specifically electronic cigarettes, and methods for their use, aiming to provide improved nicotine delivery and user satisfaction. An analysis of obviousness under 35 U.S.C. § 103 requires identifying prior art that would have motivated a person having ordinary skill in the art (PHOSITA) to combine known elements to arrive at the claimed invention with a reasonable expectation of success.

Since the provided patent text does not explicitly list external prior art documents, this analysis will rely on the general state of the art and common knowledge in the field of electronic cigarettes and nicotine formulations as implied and discussed within the patent itself prior to its priority date of May 6, 2013.

Implied Prior Art References

1. Prior Art Reference 1 (PA1): Electronic Cigarettes with Freebase Nicotine: Electronic cigarettes comprising a heating element, a liquid reservoir, and a biologically acceptable liquid carrier (such as propylene glycol and/or vegetable glycerin) for delivering freebase nicotine in an inhalable aerosol were well-known prior to the priority date of US'533. The patent itself discusses and compares its nicotine salt formulations to "nicotine freebase formulations" and notes the "lack of satisfaction of free base nicotine".
2. Prior Art Reference 2 (PA2): General Knowledge of Nicotine Salts: It was known in the art that nicotine, as an alkaloid, could form salts with various organic and inorganic acids. The patent's "Prior art keywords" include "nicotine salt" and "acid", and the patent refers to "Conflicting reports have been published regarding the transfer efficiency of free base nicotine in comparison to mono- or di-protonated nicotine salts". This indicates that nicotine salts were an explored alternative to freebase nicotine in delivery systems.
3. Prior Art Reference 3 (PA3): Basic Principles of Aerosolization Chemistry: Fundamental chemical engineering principles dictate that the physical properties of components in a liquid formulation, such as vapor pressure, melting point, and boiling point, are critical for efficient aerosol generation when heated. A PHOSITA would understand that materials need to be volatile enough to vaporize effectively at the device's operating temperature without decomposing.

Obviousness Argument Under 35 U.S.C. § 103

A PHOSITA in the field of e-cigarette liquid formulation, prior to May 6, 2013, would have been motivated to combine PA1, PA2, and PA3 to improve the user experience and nicotine delivery efficiency of electronic cigarettes.

Motivation for Combination:
Existing e-cigarettes using freebase nicotine (PA1) presented challenges related to user satisfaction and potentially the efficiency of nicotine transfer. The patent explicitly states that freebase nicotine compositions' delivery of nicotine to blood is "not necessarily comparable in blood plasma levels (Cmax and Tmax) to a traditional cigarette's nicotine delivery to blood when inhaled" and can lead to a "lack of satisfaction". This would provide a strong motivation for a PHOSITA to seek alternatives.

Given the general knowledge of nicotine salts (PA2) as a way to modify nicotine's properties, a PHOSITA would naturally consider incorporating them into e-cigarette formulations to address these deficiencies. To ensure that these nicotine salt formulations effectively generate an inhalable aerosol in a heated e-cigarette device (PA1), the PHOSITA would apply basic principles of aerosolization chemistry (PA3).

Specifically, the PHOSITA would be motivated to select acids for salt formation whose physical properties (vapor pressure, melting point, boiling point) are suitable for the typical operating temperatures of an e-cigarette (e.g., 150°C to 250°C, or 180°C to 220°C, as mentioned in the patent). The patent itself suggests this line of reasoning by stating, "the optimal nicotine salt formulation may be determined by the vapor pressure of the constituent acid," and "the nicotine salt formulations comprise an acid with a vapor pressure that is similar to the vapor pressure of free base nicotine". The goal would be to achieve efficient co-vaporization of the nicotine (either as the salt or after dissociation to freebase) and the acid, leading to improved delivery.

Through routine experimentation and optimization, a PHOSITA, guided by these motivations and principles, would systematically test various known organic acids (e.g., salicylic acid, benzoic acid, lauric acid, levulinic acid, sorbic acid, pyruvic acid, which are all mentioned in the patent) whose physical properties are readily available in chemical databases. This routine optimization process could lead to the selection of acids falling within the claimed ranges for:

• Vapor pressure (>20 mmHg at 200°C, or about 20 to 200 mmHg at 200°C).
• Melting point (<160°C, boiling point >160°C, and at least a 50-degree difference between melting point and boiling point).
• Melting point at least 40 degrees lower than an operating temperature, boiling point no more than 40 degrees lower than the operating temperature, and at least a 50-degree difference between the melting point and the boiling point.

The selection of these specific ranges of physical properties, while presented as inventive in US'533, could be seen as an expected outcome of a PHOSITA's routine efforts to optimize aerosolization parameters given the operating conditions of e-cigarettes.

Addressing Claims of Unexpected Results:
The patent counters obviousness by highlighting "unpredictable results" and "unexpected" performance, particularly regarding the rapid rate of nicotine uptake in the blood (e.g., at least 5 ng/mL at about 1.5 minutes after a first puff) and superior user satisfaction compared to freebase nicotine and other nicotine salts. The patent states, "nicotine salt formulations delivered using an e-cigarette appear comparable in Cmax and Tmax values (measuring blood plasma nicotine levels), however, not all nicotine salts perform similarly to each other or to a traditional cigarette with respect to the rate of nicotine uptake in the blood at early time periods (0-1.5 minutes). These results are unexpected".

While such unexpected results can be compelling evidence of non-obviousness, an obviousness argument would still contend that the initial motivation to combine known elements and approach the problem of improving nicotine delivery with specific acid property considerations was present. The discovery of particularly effective acids within a broader, obvious-to-explore range, or the quantification of a surprisingly good pharmacokinetic profile, might be considered a matter of degree or a "hope for success" that was ultimately realized, rather than an unmotivated departure from the prior art. For a claim to be considered obvious, it is not necessary that the exact results be predictable, only that a PHOSITA would have had reason to combine the prior art elements with a reasonable expectation of some improvement. The patent's own description of exploring various nicotine salts and their properties suggests an iterative optimization process, which can sometimes lead to results that, while better than anticipated, might still fall within the realm of routine experimentation.